ZetrOZ

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, ZetrOZ sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).

17 total trials 3 currently recruiting 11 completed early-phase tilt top decile by trial count

ZetrOZ: 17 sponsored US clinical trials, 3 recruiting.

ZetrOZ sponsors 17 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Arthritis, with 3 trials.

Top-decile sponsor footprint

ZetrOZ ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

11 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

17 total, page 1 of 1

RECRUITING Phase 2

Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

NCT06257537

RECRUITING Phase 1

Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture

NCT05883241

RECRUITING Phase 1

Sustained Acoustic Medicine for Osteoarthritis Pain

NCT05254574

NOT YET RECRUITING Phase 2

Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritis

NCT07515872

COMPLETED Phase 1

Comparative Evaluation of Sustained Acoustic Medicine Device on Circulation

NCT06510062

COMPLETED Phase 2

Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

NCT05882812

COMPLETED Phase 1

Sustained Acoustic Medicine Ultrasound Diathermy Clinical Performance

NCT05259995

COMPLETED Phase 1

Comparative Usability Evaluation of Sustained Acoustic Medicine (SAM) Devices and Topical Gel for OA Knee Pain

NCT05050448

COMPLETED

Real-World Experience of Patients Treated for Musculoskeletal Injuries With SAM in Routine Care

NCT05254470

COMPLETED Phase 1

Sustained Acoustic Medicine (SAM) Combined With a Diclofenac Ultrasound Coupling Patch for Knee Osteoarthritis

NCT04391842

COMPLETED NA

Long-Duration Ultrasound for Knee Osteoarthritis

NCT03800927

COMPLETED NA

Sustained Acoustic Medicine for Chronic Low Back Pain Secondary to Herniated Nucleus Pulposus or Other Conditions

NCT02609854

TERMINATED NA

Long Duration Therapeutic Ultrasound on Tendon Injuries

NCT02340273

COMPLETED NA

Low Intensity Ultrasound Therapy for Upper Back Pain Relief

NCT02135094

COMPLETED NA

Wearable LITUS Device for Osteoarthritis of the Knee: a Randomized Double-Blind Placebo-Controlled Trial

NCT02083861

COMPLETED NA

Long Duration Therapeutic Ultrasound for Tendon Healing

NCT02466308

TERMINATED NA

Wearable Therapeutic Ultrasound Study for Knee Osteoarthritis

NCT01993693

What is open in the ZetrOZ pipeline

3 recruiting of 17 indexed (18% open); 11 completed (65%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Arthritis (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

ZetrOZ: open-pipeline peers nationwide

Peers matched on 17 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

ZetrOZ sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1520253035 0%5%10%15%20%25% Total trials Recruiting share ZetrOZAchieve Life SciencesBioDelivery Sciences InternationalChugai PharmaceuticalConvaTecEndologixNational Institute on Deafness and Other Communication Disorders (NIDCD)NICHD Pelvic Floor Disorders NetworkSanford Health
ZetrOZ sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

ZetrOZ sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 17 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this ZetrOZ page

17 registered trials is a research-attention snapshot, not an endorsement of ZetrOZ or any single study.

  • 3 of ZetrOZ's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Arthritis is the condition ZetrOZ studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Arthritis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

ZetrOZ pipeline card: 17 registered trials from official public datasets.Report a data error.